Bataille R, Sany J
Metab Bone Dis Relat Res. 1982;4(1):39-42. doi: 10.1016/0221-8747(82)90007-8.
Acute effects of salmon calcitonin (SCT) were tested by an SCT induced hypocalcemia test (SCT delta Ca test) in 70 cases of multiple myeloma (MM) (including 52 untreated patients) with bone involvement. Response to SCT in terms of maximum induced hypocalcemia (M delta Ca) was compared to normal controls (NC) and correlated with the main presenting features and clinical status. Acute effects are significantly more marked in MM than in NC (p less than .001). There is a good correlation with the extent of lytic bone lesions (p less than .01), the presence of hypercalcemia (p less than .02) and the myeloma cell mass (p less than .05). After correction for bone involvement response to SCT (M delta Ca) was stronger in IgA lambda MM than in IgG kappa (p less than .01). It is of particular interest that acute effects are significantly more marked in cases of active disease than in non-active disease. We conclude that the SCT delta Ca test might be of practical value in the management of MM.
通过鲑鱼降钙素（SCT）诱导的低钙血症试验（SCTΔCa试验），对70例有骨受累的多发性骨髓瘤（MM）患者（包括52例未经治疗的患者）进行了SCT的急性效应测试。将最大诱导低钙血症（MΔCa）方面对SCT的反应与正常对照（NC）进行比较，并与主要临床表现和临床状态相关联。MM中SCT的急性效应明显比NC更显著（p<0.001）。其与溶骨性骨病变的程度（p<0.01）、高钙血症的存在（p<0.02）和骨髓瘤细胞量（p<0.05）有良好的相关性。校正骨受累情况后，IgAλ型MM对SCT的反应（MΔCa）比IgGκ型更强（p<0.01）。特别值得关注的是，与非活动性疾病相比，活动性疾病患者的急性效应明显更显著。我们得出结论，SCTΔCa试验在MM的管理中可能具有实际价值。
